Nebula Research & Development LLC Kal Vista Pharmaceuticals, Inc. Transaction History
Nebula Research & Development LLC
- $852 Billion
- Q4 2024
A detailed history of Nebula Research & Development LLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 11,579 shares of KALV stock, worth $138,021. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,579Holding current value
$138,021% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding KALV
# of Institutions
131Shares Held
53.3MCall Options Held
63.5KPut Options Held
36.6K-
Vr Adviser, LLC New York, NY6.25MShares$74.5 Million8.73% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.91MShares$58.6 Million1.73% of portfolio
-
Tang Capital Management LLC San Diego, CA4.89MShares$58.3 Million3.11% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.89MShares$58.3 Million2.48% of portfolio
-
Vestal Point Capital, LP New York, NY4.77MShares$56.9 Million2.4% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $293M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...